Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Emerg Infect Dis ; 26(8): 1826-1830, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32338590

RESUMO

In May 2019, we investigated monkeypox in a traveler from Nigeria to Singapore. The public health response included rapid identification of contacts, use of quarantine, and postexposure smallpox vaccination. No secondary cases were identified. Countries should develop surveillance systems to detect emerging infectious diseases globally.


Assuntos
Doenças Transmissíveis Emergentes , Mpox , Doenças Transmissíveis Emergentes/epidemiologia , Humanos , Mpox/diagnóstico , Mpox/epidemiologia , Monkeypox virus/genética , Nigéria , Singapura/epidemiologia
2.
Vaccine ; 37(29): 3925-3931, 2019 06 27.
Artigo em Inglês | MEDLINE | ID: mdl-31160102

RESUMO

Influenza outbreaks occur periodically in Long Term Care Facilities (LTCFs) and vaccination is critical in preventing influenza infections. We evaluated the influenza vaccine effectiveness (VE) during respiratory outbreaks in LTCFs reported to the Ministry of Health, Singapore in 2017. A test-negative design was used to estimate the ratio of the odds of testing positive for influenza among vaccinated individuals to the odds among unvaccinated individuals. The VE was calculated as (1-odds ratio) × 100%. For adjusted VE, the estimates were derived using logistic regression adjusted for age group, gender, month of illness, and number of days from date of illness onset till to swab collection date. Estimates by influenza subtypes and post-vaccination time periods (15-180 days & 181-365 days) were also calculated using stratified data. 264 individuals, with 118 laboratory-confirmed influenza cases [32 A(H1N1)pdm09, 75 A(H3N2), 11 A(untypable)], were included in the analysis. No one was identified to be infected with influenza B. The overall adjusted VE estimate was 40.5% (95% CI: -12.2-68.5%), while the subtype-specific adjusted VE estimates were -43.4% (95% CI: -312.4-50.2%) against A(H1N1)pdm09 and 57.1% (95% CI: 5.7-80.5%) against A(H3N2). At 15-180 days post-vaccination period, the adjusted VEs were 59.3% (95% CI: 18.0-79.8%) against all influenza, 35.4% (95% CI: -123.5-81.3%) against A(H1N1)pdm09 and 67.9% (95% CI: 22.5-86.7%) against A(H3N2). Estimates were not significant at 181-365 days post-vaccination. The influenza vaccine showed varying effectiveness among individuals in Singapore's LTCFs in 2017, with a higher effectiveness among those who were more recently vaccinated. It remains an important tool in preventing influenza infections, especially for those who are at high risk of influenza-related complications.


Assuntos
Surtos de Doenças/estatística & dados numéricos , Vacinas contra Influenza/imunologia , Influenza Humana/prevenção & controle , Assistência de Longa Duração/estatística & dados numéricos , Vacinação/estatística & dados numéricos , Potência de Vacina , Adulto , Idoso , Idoso de 80 Anos ou mais , Surtos de Doenças/prevenção & controle , Monitoramento Epidemiológico , Feminino , Humanos , Vírus da Influenza A Subtipo H1N1 , Vírus da Influenza A Subtipo H3N2 , Vacinas contra Influenza/administração & dosagem , Influenza Humana/epidemiologia , Masculino , Pessoa de Meia-Idade , Razão de Chances , Projetos de Pesquisa , Estudos Retrospectivos , Estações do Ano , Singapura/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA